Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases.
Guo J, Wang F, Hu Y, Luo Y, Wei Y, Xu K, Zhang H, Liu H, Bo L, Lv S, Sheng S, Zhuang X, Zhang T, Xu C, Chen X, Su J.
Guo J, et al. Among authors: xu k, xu c.
Cell Rep Med. 2023 Jan 17;4(1):100881. doi: 10.1016/j.xcrm.2022.100881. Epub 2023 Jan 4.
Cell Rep Med. 2023.
PMID: 36603578
Free PMC article.